Takeda: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatrics Subjects with Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response